EcoDrugPlus

Proteasome 20s Subunit Alpha 2

Ensembl ID : ENSSARG00000004328
Gene Symbol: PSMA2
1 External references
228 Possible Orthologues:

Proteasome 20s Subunit Alpha 3

Ensembl ID : ENSSARG00000002670
Gene Symbol: PSMA3
3 External references
225 Possible Orthologues:

Proteasome 20s Subunit Alpha 4

Ensembl ID : ENSSARG00000005633
Gene Symbol: PSMA4
1 External references
248 Possible Orthologues:

Proteasome 20s Subunit Alpha 6

Ensembl ID : ENSSARG00000007764
Gene Symbol: PSMA6
1 External references
279 Possible Orthologues:

Proteasome 20s Subunit Alpha 8

Ensembl ID : ENSSARG00000012993
Gene Symbol: PSMA8
3 External references
197 Possible Orthologues:

Proteasome 20s Subunit Beta 10

Ensembl ID : ENSSARG00000014126
Gene Symbol: PSMB10
3 External references
171 Possible Orthologues:

Proteasome 20s Subunit Beta 2

Ensembl ID : ENSSARG00000000409
Gene Symbol: PSMB2
1 External references
220 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSSARG00000013245
Gene Symbol: PSMB4
1 External references
213 Possible Orthologues:

Proteasome 20s Subunit Beta 6

Ensembl ID : ENSSARG00000006615
Gene Symbol: PSMB6
1 External references
217 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSSARG00000009395
Gene Symbol: PSMB7
1 External references
216 Possible Orthologues:

Proteasome 20s Subunit Beta 9

Ensembl ID : ENSSARG00000004767
Gene Symbol: PSMB9
1 External references
212 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSSARG00000012558
Gene Symbol: PSMD2
1 External references
222 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).